CNR1 and type 2 diabetes mellitus: Specifically, in vivo CB1 blockade and macrophage CB1 knockouts were demonstrated to prevent macrophage infiltration in islet cells, which alleviated T2D phenotypes such as hyperglycemia and impaired glucose-induced insulin secretion [138].